Mantle Cell Lymphoma Trial
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab, and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 Years Old with Untreated Mantle Cell Lymphoma
Mantle cell lymphoma is an aggressive form of lymphoma, and the optimal upfront treatment is still unknown. This phase II trial, led by Nina D. Wagner-Johnston, MD (Johns Hopkins University), will compare three chemotherapy regimens consisting of bendamustine, rituximab, high-dose cytarabine, and acalabrutinib and evaluate how well each one works in treating newly-diagnosed patients.